乳腺癌易感基因1核苷酸切除修复交叉互补基因1β微管蛋白Ⅲ和富脯氨酸多肽13基因mRNA的表达与原发性卵巢上皮癌临床化疗敏感性的关系  

The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer

作　　者：赵丹[1] 张伟[2] 李晓光[1] 王小兵[2] 李茉[2] 李艳芬[2] 田海梅[2] 宋培培[2] 刘静[2] 常青云[2] 吴令英[1] 

机构地区：[1]中国医学科学院北京协和医学院肿瘤医院妇瘤科,100021 [2]中国医学科学院北京协和医学院肿瘤医院生物检测中心,100021

出　　处：《中华肿瘤杂志》2012年第3期196-200,共5页Chinese Journal of Oncology

摘　　要：目的评价乳腺癌易感基因1（BRCAI）、核苷酸切除修复交叉互补基因1（ERCCl）、β微管蛋白Ⅲ（TUBB3）和富脯氨酸多肽13（PRRl3）mRNA的表达量与原发性卵巢上皮癌临床化疗敏感性的关系，以及联合BRCAl和ERCCl基因检测预测原发性卵巢上皮癌化疗敏感性的价值。方法收集46例接受肿瘤细胞减灭术的原发性卵巢上皮癌患者肿瘤标本，采用荧光定量PCR法检测BRCAl、ERCCl、TUBB3和PRRl3mRNA的相对表达量。统计分析检测结果与临床化疗疗效的关系以及联合BRCAI和ERCCl基因检测结果预测原发性卵巢上皮癌临床化疗敏感性的效率。结果在临床耐药和临床敏感的原发性卵巢上皮癌组织中，BRCAlmRNA相对表达量的对数值分别为0．673±2．143和-1．436±2．594，差异有统计学意义（P=0．008）；ERCClmRNA相对表达量的对数值分别为-0.529±1．982和-3．188±2．601，差异有统计学意义（P=0．001）；PRRl3mRNA相对表达量的对数值分别为0．828±2．123和-0．7094-2．969，差异无统计学意义（P：0．074）；TUBB3mRNA相对表达量的对数值分别为1．906±1．328和1．683±1．499，差异无统计学意义（P=0．619）。当BRCAlmRNA相对表达量的对数截点值为-0．6时，预测临床化疗敏感性的灵敏度、特异度、阳性预测值和阴性预测值分别为73．3％、75．0％、84．6％和60．0％，综合评价效果最优；当ERCClmRNA相对表达量的对数截点值为-1时，预测临床化疗敏感性的灵敏度、特异度、阳性预测值和阴性预测值分别为80．0％、68．8％、82．8％和64．7％，综合评价效果最优。联合检测BRCAl和ERCCI基因时，预测的灵敏度、特异度、阳性预测值和阴性预测值分别为86．7％、68．8％、83．9％和73．3％。结论BRCA1和ERCCImRNA的表达量与原发性卵巢上皮癌临床含铂化疗方案的敏感性呈负相关。联合BRCAl和ERCCl基因检测可以提高原发性卵巢上皮癌�Objective To evaluate the expression of BRCA1, ERCC1, TUBB3 and PRR13 mRNA and their relationship with clinical chemosensitivity in primary ovarian cancer, and to assess the predictive value of joint detection of both BRCA1 and ERCC1 genes for the treatment of primary ovarian cancer. Methods Primary epithelial ovarian tumor samples were collected from 46 patients who underwent cytoreductive surgery. Real-time quantitative PCR was used to analyze the relative expression of BRCA1, ERCC1, TUBB3 and PRR13 mRNA in those cases. The correlation of clinical chemosensitivity and the test results was statistically analyzed. The efficacy of the joint prediction of clinical chemosensitivity by combining the two drug resistance gene detection was evaluated. Results The BRCA1 mRNA relative expression logarithm in the clinical-resistant group was 0.673 ±2. 143, and clinical-sensitive group - 1. 436 ±2. 594 （P = 0. 008）. The ERCC1 mRNA relative expression logarithm in the clinical-resistant group was -0.529 ± 1. 982 and clinical-sensitive group -3. 188± 2. 601 （P = 0. 001）. BRCA1 and ERCCI expression level is negatively correlated with platinum-based chemosensitivity. The PRR13 expressions in the two groups were not significantly different （ P = 0. 074） , and the TUBB3 expressions between the two groups were also not significantly different （P = 0. 619）. When the intercept point value BRCA1 mRNA expression logarithm was - 0.6, the predictive sensitivity, specificity, positive predictive value and negative predictive value were 73.3% , 75.0% , 84.6% and 60.0%, respectively, with the best comprehensive assessment. When the intercept point value of ERCC1 mRNA expression logarithm was - 1,the predictive sensitivity, specificity, positive predictive value and negative predictive value were 80.0% , 68.8% , 82.8% and 64.7%, respectively, with the best comprehensive assessment. The combination detection of BRCA1 and ERCC1 can improve the chemotherapeutic sensitivity, specificity, positive predictive value and negativ

关 键 词：卵巢肿瘤 乳腺癌易感基因1 核苷酸切除修复交叉互补基因1 β微管蛋白 Ⅲ 富脯氨酸多肽13 抗药性 肿瘤 

分 类 号：R737.9[医药卫生—肿瘤]